SUTRO BIOPHARMA, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $50.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $28.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.00K, a 99.35% decline year-over-year.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $154.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $4.00K, a 98.52% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $271.00K, a 13.69% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $314.00K, a 17.16% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $268.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $50.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $28.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $4.00K 10-K · filed 2026-03-23 | |
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $271.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $154.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $117.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $314.00K 10-K · filed 2025-03-13 | |
| 2023-03-31 | $314.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $268.00K 10-K · filed 2025-03-13 | |
| 2022-09-30 | $85.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $2.00K 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $180.00K 10-Q · filed 2023-11-13 | |
| 2021-09-30 | $160.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $452.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $1.36M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $1.86M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $108.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $8.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $56.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $180.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $81.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $10.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $42.00K 10-Q · filed 2020-11-05 | |
| 2018-06-30 | $36.00K 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $38.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $95.00K 10-K · filed 2020-03-16 | |
| 2016-12-31 | $184.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |